Result of TORI L-03, a randomized, multicenter phase II clinical trial of erlotinib (E) or E+ fulvestrant (F) in previously treated advanced non-small cell lung cancer …

EB Garon, JM Siegfried, SM Dubinett, RM Elashoff… - Cancer Research, 2013 - AACR
Background: EGFR inhibition is an established therapy for previously treated NSCLC.
Estrogen receptors (ER) and aromatase are expressed in most NSCLC specimens in both …
被引用次数：20 相关文章

[引用][C] Result of TORI L-03, a randomized, multicenter phase II clinical trial of erlotinib (E) or E plus fulvestrant (F) in previously treated advanced non-small cell lung …

EB Garon, JM Siegfried, SM Dubinett, RM Elashoff… - Cancer …, 2013 - hero.epa.gov
Result of TORI L-03, a randomized, multicenter phase II clinical trial of erlotinib (E) or E plus
fulvestrant (F) in previously treated advanced non-small cell lung cancer (NSCLC) | Health & …